Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) EBT Margin (2016 - 2025)

Integra Lifesciences Holdings' EBT Margin history spans 17 years, with the latest figure at 0.99% for Q4 2025.

  • For Q4 2025, EBT Margin fell 410.0% year-over-year to 0.99%; the TTM value through Dec 2025 reached 34.46%, down 3333.0%, while the annual FY2025 figure was 34.46%, 3333.0% down from the prior year.
  • EBT Margin for Q4 2025 was 0.99% at Integra Lifesciences Holdings, up from 1.7% in the prior quarter.
  • Across five years, EBT Margin topped out at 18.68% in Q1 2021 and bottomed at 127.75% in Q2 2025.
  • The 5-year median for EBT Margin is 6.18% (2023), against an average of 0.49%.
  • The largest annual shift saw EBT Margin soared 1546bps in 2021 before it plummeted -12412bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 12.77% in 2021, then increased by 26bps to 16.13% in 2022, then crashed by -55bps to 7.27% in 2023, then dropped by -30bps to 5.09% in 2024, then plummeted by -81bps to 0.99% in 2025.
  • Per Business Quant, the three most recent readings for IART's EBT Margin are 0.99% (Q4 2025), 1.7% (Q3 2025), and 127.75% (Q2 2025).